A preliminary study of the dopamine DA1agonist fenoldopam in the treatment of chronic left ventricular failure due to ischaemic heart disease

✍ Scribed by T. M. MacDonald; R. F. Jeffrey; A. L. Muir; M. R. Lee

• Publisher: Springer
• Year: 1990
• Tongue: English
• Weight: 219 KB
• Volume: 38
• Category: Article
• ISSN: 0031-6970
• DOI: 10.1007/bf00265985

✦ Synopsis

The effects of chronic oral fenoldopam in the treatment of NYHA grade II-III heart failure secondary to ischaemic heart disease, were studied in a placebo controlled, double blind, randomised, parallel group fashion in 20 patients. Nine patients taking placebo and six taking fenoldopam completed the study. Adverse events were similar in each group. There were no significant changes in exercise capacity, ejection fraction, body weight or symptom questionnaires with either treatment. This preliminary study has not revealed any benefit of fenoldopam in heart failure due to ischaemic heart disease.